TABLE 2.
The response rate of the ALI PDOs was determined by measuring the area of viable cells in comparison to the whole area with Fiji.
| ALI PDO | Treatment | Response |
| Control | – | |
| 1 | Cabozantinib | + |
| Nivolumab | ++ | |
| Control | – | |
| 2 | Cabozantinib | ++ |
| Nivolumab | +++ | |
| Control | – | |
| 3 | Cabozantinib | ++ |
| Nivolumab | +++ | |
| Control | – | |
| 4 | Cabozantinib | +++ |
| Nivolumab | ++ | |
| Control | – | |
| 5 | Cabozantinib | ++ |
| Nivolumab | ++ | |
| Control | – | |
| 6 | Cabozantinib | ++ |
| Nivolumab | ++ | |
| Control | – | |
| 7 | Cabozantinib | – |
| Nivolumab | +++ | |
| Control | – | |
| 8 | Cabozantinib | ++ |
| Nivolumab | +++ | |
| Control | – | |
| 9 | Cabozantinib | ++ |
| Nivolumab | +++ | |
| Control | – | |
| 10 | Cabozantinib | – |
| Nivolumab | – |
“−“: no response, “+”: weak response (up to 1/3 reduction in viablility), “++”: medium response (up to 2/3 reduction in viability), and “+++”: strong response more than (2/3 reduction in viability; B).